Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution

Laggis, Caroline; Lamb, Andrew; Secrest, Aaron M.; Ufkes, Nicole; Halwani, Ahmad; Tao, Randa; Gaffney, David K.; Miles, Rodney R.; Florell, Scott R.; Wada, David A.

doi:10.1111/jdv.16790

Cited by 4 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 3 Oral retinoid-based therapy was also described as a therapeutic option in two other studies. Laggis et al reported, for acitretin in combination with RT or TSEB, response rates of 24% (CR), 48% (PR) and 28% (NR); 32 single-agent isotretinoin (32 patients) was a common therapy in Wieser et al’s cohort, 3 though response rates were specifically described only for radiation therapy protocols (ie, CR rates of 50%, 33.3%, 42.8% for local RT, TSEB and both, respectively). Complete and partial response rates of 62% and 38% in the local RT group and 53% and 43% in the TSEB group, respectively, were reported in the Dutch experience.…”

Section: Resultsmentioning

confidence: 99%

“…A total of 38 records was initially identified through a literature search, 19 of which were duplicates. After screening for eligibility and inclusion criteria, 15 articles were ultimately included [20][21][22][23][24][25][26][27][28][29][30][31][32] (Table 1). Most publications were case reports (n=7), followed by case series (n=4), original articles (n=3), and clinical image (n=1).…”

Section: Resultsmentioning

confidence: 99%

“…Combination treatment with phototherapy seems to be advisable. 27 , 28 Ionizing treatments such as radiotherapy and TSEBT, especially if combined with bexarotene, appear effective, at least in the short term, yet the need for coordination between different specialists and, in the case of TSEBT, between different centers can represent a limitation for their use in clinical practice 3 , 5 , 32 , 41 ( Figure 3 ). Moreover, a TSEBT-based therapeutical approach has proved to significantly improve emotional domains of quality of life in MF patients.…”

Section: Discussionmentioning

confidence: 99%

“…4 Looking at the recent data reported in the literature, more than half of the analyzed papers did not include advanced disease stages (≥IIB), thus showing generally higher ORR rates for the therapies reported. [20][21][22][23][24][25][26][27][28][29][30][31][32] On the contrary, looking at those studies which included more advanced stages, such as the papers by van Santeen et al and Laggis et al, a significantly higher fluctuation of ORR could be observed (ie, PR and CR ranging from 25-24% to 48-51%, respectively). 5,32 Our case history shows quite similar responses, with CR achieved mainly in early stages.…”

Section: Discussionmentioning

confidence: 99%

“…[20][21][22][23][24][25][26][27][28][29][30][31][32] On the contrary, looking at those studies which included more advanced stages, such as the papers by van Santeen et al and Laggis et al, a significantly higher fluctuation of ORR could be observed (ie, PR and CR ranging from 25-24% to 48-51%, respectively). 5,32 Our case history shows quite similar responses, with CR achieved mainly in early stages. Moreover, despite being traditionally considered an aggressive variant of MF, metastatic cases of FMF described in the literature in the last 5 years are in line with our case series and generally represent a small percentage of the patients.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice

Roccuzzo¹,

Mastorino²,

Gallo³

et al. 2022

CCID

View full text Add to dashboard Cite

Introduction Folliculotropic mycosis fungoides (FMF) is the most frequent variant of mycosis fungoides (MF), with clinical features which differ from the classic form. As for therapeutic options, the latest guidelines on MF agree on a stage-driven strategy, in consideration of clinical presentation, symptom burden and patient’s comorbidities. Materials and Methods A search on MEDLINE, PubMed, Scopus and Cochrane Library was conducted to gather the latest evidence on FMF clinical management. Manuscripts published in the last five years (January 2017–April 2022) were included. Our single-center experience was also described. Results A total of 15 articles were analyzed, with a total of 432 patients (disease stage from IA to IVA2). The most widely-used treatment was psoralen ultra-violet A (PUVA) in monotherapy or in association with other drugs. Oral retinoid-based therapy was also described as a therapeutic option alone or in combination. Other therapy reported were based on Brentuximab Vedotin, Mogamulizumab, Carmustine, topical steroids, tazarotene and excimer laser, interferon, nitrogen mustard, imiquimod, systemic chemotherapy, extracorporeal photopheresis and stem cell transplantation. Discussion FMF is characterized by specific clinical-pathologic features. Advanced forms assume characteristics more similar to classic MF (infiltrated plaques and nodules), whilst early stages can present in a wide range of clinical forms (acneiform lesions, follicular-like keratoses, erythematous patches). As for therapeutic options, in absence of specific guidelines, a high number of treatments are described in clinical practice, with variable results. Phototherapy in all its forms, especially as PUVA, appears to have the greatest initial therapeutic success. Retinoids, although widely used, appear to be poorly effective in monotherapy, particularly acitretin. Combination treatment with phototherapy seems to be advisable. Ionizing treatments, such as radiotherapy and TSEBT, appear effective, at least in the short term. Overall, an integrated approach is mandatory for the inconstant course of the disease and its multidisciplinary nature.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice

Roccuzzo¹,

Mastorino²,

Gallo³

et al. 2022

CCID

View full text Add to dashboard Cite

show abstract

Primary cutaneous T‐cell lymphomas in childhood and adolescence

Wohlmuth-Wieser

2021

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Primary cutaneous lymphomas are extranodal non‐Hodgkin lymphomas of T‐ or B‐ cell origin, that predominantly affect older patients but have been reported in all age groups and as early as in the first years of life. Diagnosis of cutaneous lymphomas is challenging and requires high clinical suspicion and close collaboration between dermatologists, pediatric oncologists and pathologists. Skin involvement of non‐Hodgkin lymphomas in children or adolescents can either be primary cutaneous or secondary due to an underlying nodal lymphoma. The most common primary cutaneous lymphomas encountered in children are of T‐cell origin, with mycosis fungoides being the most prevalent cutaneous T‐cell lymphoma, followed by CD30+ lymphoproliferative disorders. While cutaneous lymphomas share clinicopathologic characteristics between juvenile and adult forms, there are important differences in terms of clinical presentation, diagnosis and treatment. The hypopigmented variant of mycosis fungoides seems to be overrepresented in the pediatric age group. Prognosis and treatment of mycosis fungoides are stage dependent. The majority of children present with early‐stage disease and respond well to topical corticosteroids and phototherapy.

show abstract

Primär kutane T‐Zell‐Lymphome im Kindes‐ und Jugendalter

Wohlmuth-Wieser

2021

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Primär kutane Lymphome sind extranodale T‐ oder B‐Zell‐Non‐Hodgkin‐Lymphome, die vorwiegend ältere Patienten betreffen, aber in allen Altersgruppen einschließlich der ersten Lebensjahre auftreten können. Die Diagnose kutaner Lymphome ist eine Herausforderung und erfordert einen hohen klinischen Verdacht sowie enge Zusammenarbeit zwischen Dermatologen, pädiatrischen Onkologen und Pathologen. Generell müssen primär kutane Lymphome von sekundär kutanen Lymphomen, welche meist von nodalen oder extranodalen Lymphomen ausgehen, unterschieden werden. Die häufigsten primär kutanen Lymphome im Kindesalter sind T‐Zell Lymphome, wobei Mycosis fungoides das häufigste kutane T‐Zell‐Lymphom darstellt, gefolgt von CD30+ lymphoproliferativen Erkrankungen. Während klinisch‐pathologische Merkmale kutaner Lymphome bei Jugendlichen und Erwachsenen ähnlich sind, gibt es wichtige Unterschiede bezüglich klinischer Präsentation, Diagnose und Behandlung. Die hypopigmentierte Variante der Mycosis fungoides scheint in der pädiatrischen Altersgruppe überrepräsentiert zu sein. Prognose und Behandlung der Mycosis fungoides sind stadienabhängig. Die Mehrheit der Kinder weist ein frühes Krankheitsstadium auf und spricht gut auf topische Kortikosteroide und Phototherapie an.

show abstract

Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution

Cited by 4 publications

References 10 publications

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice

Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice

Primary cutaneous T‐cell lymphomas in childhood and adolescence

Primär kutane T‐Zell‐Lymphome im Kindes‐ und Jugendalter

Contact Info

Product

Resources

About